@Article{oncologie.2022.026248,
AUTHOR = {Xuelian Du, Hao Shi, Haiyan Liu, Linghua Zhou, Anqun Xie, Jufang Guo},
TITLE = {Angiogenic Gene <i>PTK2</i> is a Potential Biomarker of Gestational Diabetes Mellitus and is Significantly Associated with Breast Cancer Immune Infiltration},
JOURNAL = {Oncologie},
VOLUME = {24},
YEAR = {2022},
NUMBER = {4},
PAGES = {769--787},
URL = {http://www.techscience.com/oncologie/v24n4/51005},
ISSN = {1765-2839},
ABSTRACT = {<b>Background:</b> Gestational diabetes mellitus (GDM) affects the health of numerous women around the world. A
recent study has shown that GDM is associated with an increased incidence of cancer. In this study, we aimed
to explore the possible shared mechanisms and potential common therapeutic targets between GDM and cancer.
<b>Methods:</b> The limma package was used to identify differentially expressed genes (DEGs) in GDM. The Cytoscape
plugin cytoHubba was used to screen hub genes. The CIBERSORT algorithm was used to explore the correlation
between hub genes and immunity. Cox regression analysis was used to assess the relationship between protein
tyrosine kinase 2 (<i>PTK2</i>) expression and prognosis in pan-cancer. Single-sample gene set enrichment analysis
(ssGSEA) and CIBERSORT were used to assess the correlation between <i>PTK2</i> and immunity in cancer. Mutation
and methylation analyses of <i>PTK2</i> were assessed using Spearman’s correlation test. <b>Results: </b>A total of 871 DEGs
were identified, among which the hub genes were significantly highly expressed in GDM and had a strong association with immunity. Pan-cancer analysis revealed that <i>PTK2</i> was significantly overexpressed in multiple types
of cancer. Survival analysis showed that <i>PTK2</i> was significantly associated with poor prognosis in multiple cancers. Mutational analysis revealed that copy number variation of <i>PTK2</i> mediated abnormal expression of mRNA,
and expression of <i>PTK2</i> was significantly correlated with tumor mutational burden of various cancers. Immune
correlation analysis showed pre-correlation of <i>PTK2</i> with breast cancer, and patients with low expression of <i>PTK2</i>
could benefit more from immunotherapy. GSEA enrichment analysis was enriched in adaptive immune response,
which verified the strong association of <i>PTK2</i> with immunity in breast cancer. <b>Conclusions: </b><i>PTK2</i> was involved
in the immune response of GDM and breast cancer and may be a novel clinical prognostic marker and potential
common therapeutic target for GDM and breast cancer.},
DOI = {10.32604/oncologie.2022.026248}
}